With reference to advanced NSCLC, single-agent PD-1 is the current standard of care for non-oncogene addicted NSCLC with high PD-L1 expression, while combinations involving ICIs and chemotherapy are employed with absent or low PD-L1 expression [1]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.